Patents by Inventor Peter Turecek

Peter Turecek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Resorption Enhancers As Additives To Improve The Oral Formulation Of Non-Anticoagulant Sulfated Polysaccharides
    Publication number: 20130035288
    Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.
    Type: Application
    Filed: July 18, 2012
    Publication date: February 7, 2013
    Inventors: Peter Turecek, Susanne Vejda
  • Polymer-von Willebrand factor-conjugates
    Patent number: 8357779
    Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: January 22, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann
  • VON WILLEBRAND FACTOR- AND FACTOR VIII-POLYMER CONJUGATES HAVING A RELEASABLE LINKAGE
    Publication number: 20130012442
    Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicants: NEKTAR THERAPEUTICS, Baxter Healthcare SA, Baxter International Inc.
    Inventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
  • NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE
    Publication number: 20130011900
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Application
    Filed: June 4, 2012
    Publication date: January 10, 2013
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
    Patent number: 8349800
    Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 8, 2013
    Assignees: Nektar Therapeutics, Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
  • Preparative purification process for human furin
    Patent number: 8343748
    Abstract: Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on CAPTO MMC™ (mixed cation exchange/hydrophobic interaction gel) resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after CAPTO MMC™ (mixed cation exchange/hydrophobic interaction gel) chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: January 1, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter Matthiessen, Stefan Romeder-Finger, Peter Turecek, Hans-Peter Schwarz
  • THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME
    Publication number: 20120329127
    Abstract: The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein.
    Type: Application
    Filed: May 25, 2012
    Publication date: December 27, 2012
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Juergen Siekmann, Alfred Weber, Hanspeter Rottensteiner, Peter Turecek
  • MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE
    Publication number: 20120322737
    Abstract: The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.
    Type: Application
    Filed: April 20, 2012
    Publication date: December 20, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Hans-Peter Schwarz, Peter Turecek
  • TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
    Publication number: 20120316116
    Abstract: The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII.
    Type: Application
    Filed: June 11, 2012
    Publication date: December 13, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Friedrich Scheiflinger, Peter Turecek, Bruce Ewenstein, Wing Yen Wong, Tobias M. Suiter
  • FACTOR VIII POLYMER CONJUGATES
    Publication number: 20120232252
    Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
    Type: Application
    Filed: September 23, 2011
    Publication date: September 13, 2012
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Peter TURECEK, Juergen SIEKMANN
  • MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN
    Publication number: 20120190096
    Abstract: The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water soluble fatty acid derivative under conditions that allow conjugation.
    Type: Application
    Filed: December 16, 2011
    Publication date: July 26, 2012
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Juergen Siekmann, Richard Scheinecker, Hanspeter Rottensteiner, Peter Turecek
  • CHEMICALLY MODIFIED FACTOR IX
    Publication number: 20120177625
    Abstract: The present invention discloses a chemically modified FIX, wherein the activation peptide region contains a covalently coupled water-soluble hydrophilic polymer.
    Type: Application
    Filed: December 29, 2011
    Publication date: July 12, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Peter Turecek, Freidrich Scheiflinger
  • Von Willebrand Factor- and Factor VIII-Polymer Conjugates Having a Releasable Linkage
    Publication number: 20120142594
    Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.
    Type: Application
    Filed: February 10, 2012
    Publication date: June 7, 2012
    Applicants: Baxter International Inc., NEKTAR THERAPEUTICS
    Inventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
  • Polymer-Von Willebrand Factor-Conjugates
    Publication number: 20120135462
    Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 31, 2012
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann
  • Modified recombinant factor VIII and von Willebrand factor and methods of use
    Patent number: 8173597
    Abstract: The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: May 8, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Hans-Peter Schwarz, Peter Turecek
  • Modified Blood Factors Comprising a Low Degree of Water Soluble Polymer
    Publication number: 20120076749
    Abstract: The present invention relates, in general, to materials and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood factor but exhibit biological activity similar to or better than molecules having a higher number of water soluble polymer moieties.
    Type: Application
    Filed: September 23, 2011
    Publication date: March 29, 2012
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Juergen Siekmann, Hanspeter Rottensteiner
  • von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
    Patent number: 8133865
    Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: March 13, 2012
    Assignees: Nektar Therapeutics, Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
  • METHODS FOR DIFFERENTIATING PLASMA- DERIVED PROTEIN FROM RECOMBINANT PROTEIN IN A SAMPLE
    Publication number: 20120040379
    Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.
    Type: Application
    Filed: October 26, 2011
    Publication date: February 16, 2012
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • Methods for differentiating plasma-derived protein from recombinant protein in a sample
    Patent number: 8114633
    Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: February 14, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE
    Publication number: 20120035344
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Application
    Filed: July 29, 2011
    Publication date: February 9, 2012
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Andreas Ivens, Peter Turecek, Oliver Zoechling